Effects of the anthelmintic drug PF1022A on mammalian tissue and cells

Biochemical Pharmacology

Volumn 77, Issue 8, 2009, Pages 1437-1444

  Dornetshuber, R ^a,b   Kamyar, M R ^a   Rawnduzi, P ^a   Baburin, I ^a   Kouri, K ^a   Pilz, E ^a   Hornbogen, T ^c   Zocher, R ^c   Berger, W ^b   Lemmens Gruber, R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Anthelmintics; Apoptosis; Cytotoxicity; Ionophore; PF1022A

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTHELMINTIC AGENT; CALCIUM; IONOPHORE; PF 1022 A; POTASSIUM; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SODIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTHELMINTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GUINEA PIG; HUMAN; HUMAN CELL; ILEUM; ILEUM CONTRACTION; NONHUMAN; POTASSIUM CELL LEVEL; PRIORITY JOURNAL; SODIUM CELL LEVEL;

ANIMALS; ANTINEMATODAL AGENTS; CALCIUM; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEPSIPEPTIDES; GUINEA PIGS; HUMANS; ILEUM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROELECTRODES; MUSCLE CONTRACTION; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM; PROTEIN BINDING; RECEPTORS, GABA; SODIUM; XENOPUS LAEVIS;

EID: 62549159516     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.01.005     Document Type: Article

References (51)

1. Bundy D.A., and de Silva N.R. Can we deworm this wormy world?. Br Med Bull 54 (1998) 421-432
2. Waller P.J. Anthelmintic resistance. Vet Parasitol 72 (1997) 391-412
3. von Samson-Himmelstjerna G., Harder A., Sangster N.C., and Coles G.C. Efficacy or two cyclooctadepsipeptides, PF1022A and emodepsidde, against anthelmintic-resistant nematodes in sheep and cattle. Parasitology 130 (2005) 343-347
4. Geary T.G., Sangster N.C., and Thompson D.P. Frontiers in anthelmintic pharmacology. Vet Parasitol 84 (1999) 275-295
5. Sasaki T., Takagi M., Yaguchi T., Miyadoh S., Okada T., and Koyama M. A new anthelmintic cyclodepsipeptide, PF1022A. J Antibiot (Tokyo) 45 (1992) 692-697
6. Conder G.A., Johnson S.S., Nowakovski D.S., Blake T.E., Dutton F.E., Nelson S.J., et al. Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models. J Antibiot (Tokyo) 48 (1995) 820-823
7. Kachi S., Terada M., and Hashimoto H. Effect of PF1022A on adult Angiostrongylus cantonensisin the pulmonary arteries and larvae migrating into the central nervous system in rats. Parasitol Res 81 (1995) 631-637
8. von Samson-Himmelstjerna G., Harder A., Schmieder T., Kalbe J., and Mencke N. In vivo activities of the new anthelmintic depsipeptide PF1022A. Parasitol Res 86 (2000) 194-199
9. Zahner H., Taubert A., Harder A., and von Samson-Himmelstjerna G. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int J Parasitol 31 (2001) 1515-1522
10. Mentz M.B., and Graeff-Teixeira C. Drug trials for treatment of human angiostrongliasis. Rev Inst Med Trop Sao Paulo 45 (2003) 179-184
11. Weckwerth W., Miyamoto K., Iinuma K., Krause M., Glinski M., Storm T., et al. Biosynthesis of PF1022A and related cyclooctadepsipeptides. J Biol Chem 275 (2000) 17909-17915
12. Krause M. Untersuchungen zur Biosynthese des Cyclooctadepsipeptids PF1022A. Dissertation, TU, Berlin; 1998.
13. Yanai K., Sumida N., Okakura K., Moriya T., Watanabe M., and Murakami T. Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes. Nat Biotechnol 22 (2004) 848-855
14. Jeschke P., Iinuma K., Harder A., Schindler M., and Murakami T. Influence of the cyclooctadepsipeptide PF1022A and PF1022E as natural products on the design of the semi-synthetic anthelmintics such as emodepside. Parasitol Res 97 (2005) 511-516
15. Jeschke P., Harder A., Etzel W., Gau W., Thielking G., Bonse G., et al. Synthesis and anthelmintic activity of thioamide analogues of cyclic octadepsipeptides such as PF1022A. Pest Manage Sci 57 (2001) 1000-1006
16. Jeschke P., Harder A., von Samson-Himmelstjerna G., Etzel W., Gau W., Thielking G., et al. Synthesis of anthelmintically active N-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A. Pest Manage Sci 58 (2002) 1205-1215
17. Dyker H., Harder A., and Scherkenbeck J. Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. Bioorg Med Chem Lett 14 (2004) 6129-6132
18. Dutton F.E., and Nelson S.J. Synthesis of PF1022A, an anthelmintic cyclodepsipeptide. J Antibiot (Tokyo) 47 (1994) 1322-1327
19. Dutton F.E., Lee B.H., Johnson S.S., Coscarelli E.M., and Lee P.H. Restricted conformation analogues of an anthelmintic cyclodepsipeptide. J Med Chem 46 (2003) 2057-2073
20. Lee B.H., Dutton F.E., Thompson D.P., and Thomas E.M. Generation of a small library of cyclodepsipeptide PF1022A analogues using a cyclization-cleavage method with oxime resin. Bioorg Med Chem Lett 12 (2002) 353-356
21. Scherkenbeck J., Jeschke P., and Harder A. PF1022A and related cyclodepsipeptides-a novel class of anthelmintics. Curr Top Med Chem 2 (2002) 759-777
22. Scherkenbeck J., Harder A., Plant A., and Dyker H. PF1022A-a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. Bioorg Med Chem Lett 8 (1998) 1035-1040
23. Saeger B., Schmitt-Wrede H.P., Dehnhardt M., Benten W.P.M., Krücken J., Harder A., et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J 15 (2001) 1332-1354
24. Harder A., Schmitt-Wrede, Krücken J., Marinovski P., Wunderlich F., Willson J., et al. Cyclooctadepsipeptides-an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents 22 (2003) 318-331
25. Harder A., Holden-Dye L., Walker R., and Wunderlich F. Mechanisms of action of emodepside. Parasitol Res 97 (2005) S1-S10
26. Harder A., and von Samson-Himmelstjerna G. Cyclooctadepsipeptides-a new class of anthelmintically active compounds. Parasitol Res 88 (2002) 481-488
27. Chen W., Terada M., and Cheng J.T. Characterization of subtypes of gamma-aminobutyric acid receptors in an Ascaris muscle preparation by binding assay and binding of PF1022A, a new anthelmintic, on the receptor. Parasitol Res 82 (1996) 97-101
28. Gessner G., Meder S., Rink T., Boheim G., Harder A., Jeschke P., et al. Ionophore and anthelmintic activity of PF1022A, a cyclooctadepsipeptide, are not related. Pest Sci 48 (1996) 399-407
29. Zhang L., Yan K., Zhang Y., Huang R., Bian J., Zheng C., et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci USA 104 (2007) 4606-4611
30. Fukuda T., Arai M., Yamaguchi Y., Masuma R., Tomoda H., and Omura S. New beauvericins, potentiators of antifungal miconazole activity, produced by Beauveria sp. FKI-1366. Taxonomy, fermentation, isolation and biological properties. J Antibiot 57 (2004) 110-116
31. Dornetshuber R., Heffeter P., Kamyar M., Peterbauer T., Berger W., and Lemmens-Gruber R. Enniatin induces apoptosis and exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem Res Toxicol 20 (2007) 465-473
32. Lin H.I., Lee Y.J., Chen B.F., Tsai M.C., Lu J.L., Chou C.J., et al. Involvement of Bcl-family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells. Cancer Lett 239 (2005) 248-259
33. Jow G.M., Chou C.J., Chen B.F., and Tsai J.H. Beauvericin induces cytotoxic effects in human acute lymphoblastic leukemia cells through cytochrome c release, caspase 3 activation: the causative role of calcium. Cancer Lett 216 (2004) 165-173
34. Zhan J., Burns A.M., Liu M.X., Faeth S.H., and Gunatilaka A.A.L. Search for cell motility and angiogenesis inhibitors with potential anticancer activity: beauvericin and other constituents of two endophytic strains of Fusarium oxysporum. J Nat Prod 70 (2007) 227-232
35. Jeschke P., Benet-Buchholz J., Harder A., Etzel W., Schindler M., Gau W., et al. Synthesis and anthelmintic activity of substituted (R)-phenyllactic acid containing cyclohexadepsipeptides. Bioorg Med Chem Lett 16 (2006) 4410-4415
36. Shen D.W., Cardarelli C., Hwang J., Cornwell M., Richert N., Ishii S., et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261 (1986) 7762-7770
37. Bunz F., Fauth C., Speicher M.R., Dutriaux A., Sedivy J.M., Kinzler K.W., et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 62 (2002) 1129-1133
38. Waldman T., Kinzler K.W., and Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55 (1995) 5187-5190
39. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
40. Kamyar M.R., Rawnduzi P., Studenik C., Kouri K., and Lemmens-Gruber R. Investigation of the electrophysiological properties of enniatin. Arch Biochem Biophys 429 (2004) 215-223
41. A receptors containing gamma1 subunits. Mol Pharmacol 69 (2006) 640-649
42. Methfessel C., Witzemann V., Takahashi T., Mishina M., Numa S., and Sakmann B. Patch clamp measurements on Xenopus laevis oocytes: currents through endogenous channels and implanted acetylcholine receptor and sodium channels. Pflugers Arch 407 (1986) 577-588
43. Baburin I., Beyl S., and Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch 453 (2006) 117-123
44. Heffeter P., Jakupec M.A., Körner W., Chiba P., Pirker C., Dornetshuber R., et al. Multidrug-resistant cancder cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 73 (2007) 1873-1886
45. Martin R.J., Harder A., Londerhausen M., and Jeschke P. Anthelmintic actions of the cyclic depsipeptide PF1022A and its electrophysiological effects on muscle cells of Ascaris suum. Pest Sci 48 (1996) 343-349
46. Kouri K., Duchen M.R., and Lemmens-Gruber R. Effects of beauvericin on the metabolic state and ionic homeostasis of ventricular myocytes of the guinea pig. Chem Res Toxicol 18 (2005) 1661-1668
47. Kamyar M.R., Kouri K., Rawnduzi P., Studenik C., and Lemmens-Gruber R. Effects of moniliformin in presence of cyclohexadepsipeptides on isolated mammalian tissue and cells. Toxicol In Vitro 20 (2006) 1284-1291
48. Kouri K., Lemmens M., and Lemmens-Gruber R. Beauvericin induced channels in ventricular myocytes and artificial membranes. Biochim Biophys Acta 1609 (2003) 203-210
49. Ivanov V.T., Evstratov A.V., Sumskaya L.V., Melnik E.I., Chumburidze T.S., Portnova S.L., et al. Sandwich complexes as a functional form of the enniatin ionophores. FEBS Lett 36 (1973) 65-71
50. Ovchinnikov Y.A., Ivanov V.T., Evstratov A.V., Mikhaleva I.I., Bystrov V.F., Portnova S.L., et al. The enniatin ionophores. Conformation and ion binding properties. Int J Peptide Protein Res 6 (1974) 465-498
51. 2+. Chem Res Toxicol 18 (2005) 825-833